Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase

被引：84

作者：

Kahn, Jennifer Nielsen

Garcia-Effron, Guillermo

Hsu, Ming-Jo

Park, Steven

Marr, Kieren A.

Perlin, David S.

机构：

[1] Univ Med & Dent New Jersey, New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ 07103 USA

[2] Merck Res Labs, Rahway, NJ USA

[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 05期

关键词：

D O I：

10.1128/AAC.00067-07

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

A Candida krusei strain from a patient with acute myelogenous leukemia that displayed reduced susceptibility to echinocandin drugs contained a heterozygous mutation, T2080K, in FKS1 The resulting Phe655 -> Cys substitution altered the sensitivity of glucan synthase to echinocandin drugs, consistent with a common mechanism for echinocandin resistance in Candida spp.

引用

收藏

页码：1876 / 1878

页数：3

相关论文

共 18 条

[1] Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? [J].

Charlier, C ;

Hart, E ;

Lefort, A ;

Ribaud, P ;

Dromer, F ;

Denning, DW ;

Lortholary, O .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (03) :384-410

[2] Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy [J].

Hakki, Morgan ;

Staab, Janet F. ;

Marr, Meren A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) :2522-2524

[3]

JACOBSEN MD, 2006, J CLIN MICROBIOL

[4] Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility [J].

Katiyar, Santosh ;

Pfaller, Michael ;

Edlind, Thomas .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (08) :2892-2894

[5] Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis [J].

Laverdière, M ;

Lalonde, RG ;

Baril, JG ;

Sheppard, DC ;

Park, S ;

Perlin, DS .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (04) :705-708

[6] Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin [J].

Miller, CD ;

Lomaestro, BW ;

Park, S ;

Perlin, DS .

PHARMACOTHERAPY, 2006, 26 (06) :877-880

[7] Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality [J].

Morrell, M ;

Fraser, VJ ;

Kollef, MH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3640-3645

[8]

National Committee for Clinical Laboratory Standards, 2002, M27A2 NAT COMM CLIN

[9] Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States [J].

Ostrosky-Zeichner, L ;

Rex, JH ;

Pappas, PG ;

Hamill, RJ ;

Larsen, RA ;

Horowitz, HW ;

Powderly, WG ;

Hyslop, N ;

Kauffman, CA ;

Cleary, J ;

Mangino, JE ;

Lee, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3149-3154

[10] Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp isolates [J].

Park, S ;

Kelly, R ;

Kahn, JN ;

Robles, J ;

Hsu, MJ ;

Register, E ;

Li, W ;

Vyas, V ;

Fan, H ;

Abruzzo, G ;

Flattery, A ;

Gill, C ;

Chrebet, G ;

Parent, SA ;

Kurtz, A ;

Teppler, H ;

Douglas, CA ;

Perlin, DS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3264-3273